Loading
Journal of Clinical Haematology
ISSN: 2766-4686
Featured Articles
Concomitant Langerhans Cell Histiocytosis and Chronic Myelomonocytic Leukaemia Responding to 5-azacitidine
Peter Brændstrup, Dennis Lund Hansen, Louise Kristensen, Henrik Frederiksen, Hanne E. H. Møller
Langerhans cell histiocytosis (LCH) is a rare, clonal, haematological disease of myeloid origin involving infiltration of neoplastic cells resembling Langerhans cells in various tissues. LCH cells express normal Langerhans cell markers such as CD1a, Langerin (CD207), and S100.
J Clin Haematol, 2022, Volume 3, Issue 2, p61-65 | DOI: 10.33696/haematology.3.050
Multiple Myeloma with Neutrophilia: Two Etiologic Pathways for a Rare Presentation of a Common Diagnosis
Rachel Rose Hall, Christine MG Schammel, Jennifer Bell Knight
Multiple myeloma (MM) is a common hematologic malignancy, with 32,110 new cases diagnosed in the United States in 2019, resulting in 12,960 deaths. While neutrophilia
is also a common entity, it most often arises secondary to other etiologies, such as infection or inflammatory processes.
Gemcitabine in the Era of Cancer Immunotherapy
Katarzyna Piadel, Angus George Dalgleish, Peter Lawrence Smith
Gemcitabine is a synthetic pyrimidine nucleoside analogue which is administered intravenously as a chemotherapeutic to treat numerous cancers. Gemcitabine requires transport into cells and activation by phosphorylation, the resulting gemcitabine triphosphate is incorporated into newly synthesized DNA during cell division, inhibiting further DNA synthesis and causing cell death. Gemcitabine is used to treat cancers including those of the pancreas, lung, breast, colon, and ovary either as first or second line treatments as a single agent or in combination.
J Clin Haematol, 2020, Volume 1, Issue 4, p107-120 | DOI: 10.33696/haematology.1.016
When Should Transplant Physicians Think about Familial Blood Cancers?
Lucy A. Godley
A 56-year-old Caucasian man was referred to an academic medical center for consideration of allogeneic hematopoietic stem cell transplantation (HSCT). One year earlier, he had seen his primary care physician for increased fatigue and decreased exercise tolerance, and a complete blood cell count showed a total white blood cell count of 2500/μL, hemoglobin of 7.2g/dL, and a platelet count of 110,000/μL. The white blood cell differential showed an absolute neutrophil count of 900/μL. The patient was referred to a hematologist who performed a bone marrow biopsy that showed a myelodysplastic syndrome with del(5q).
J Clin Haematol, 2020, Volume 1, Issue 3, p78-84 | DOI: 10.33696/haematology.1.012